Pharmaceutical Manufacturing Of R&D Eiffciency Evaluation In China

R&D activities is a touch simply activities, unknown coefficient is very big, it isdifficult to predict its expected returns. With the development of world economy,people pay more and more attention to R&D activities, also more and moreconsciousness to the power of knowledge, each department have stepped up researchand development efforts, but not all of the R&D input can bring expected high yields,this is because of R&D investment in research and development department of theutilization is not high, leading to R&D activities is invalid. After the preliminaryjudgment, our country medicine manufacturing R&D efficiency is not high, it will notonly influence the industry’s technology progress and development, but also theassociated effect through to related industry technology progress and industrialupgrading. Based on this, the medicine manufacturing efficiency will R&D is verysignificant and profound significance, this article through to the pharmaceuticalmanufacturing efficiency evaluation of R&D, just want to know what factors affectedits efficiency increase, and seek policy and improving methods.In this paper, the DEA model and the DEA model based on the Malmquistindex method to our country medicine manufacturing R&D efficiency, points of theregion chat of the static and dynamic measurement and evaluation. Static measureresults show that: the pharmaceutical industry wide distribution, in various provincesand municipalities and counties, but each medical enterprise, the market share of thesmall; Chemical industry since each enterprise on a smaller scale, the value of low, noform scale advantage, that its research and development activities without efficiency;The central region in central China because, opposite for the geographical location isclosed, the traffic is not very convenient, so its economic development is not verygood, cause its technology also is relatively backward, the scale is small, the tworeasons that research and development activities in central China no effect; Dynamicmeasurement results show: in recent years, our country medicine manufacturing R&Defficiency on the whole is positive development efforts with advanced countries andconfirm the output value is increased, but the growth rate of output value is not very high, can’t and other leading countries, however, the gap is still some; In much of thetechnological progress’s changing index is negative, this shows that our countrymedicine manufacturing industry is in the technical bottleneck; Technical progresschanges small scale, index effect is not obvious in Chinese chemical industry restrictthe R&D efficiency to raise the level of; The central region in central China because,opposite for the geographical location is closed, the traffic is not very convenient, soits economic development is not very good, cause its technology also is relativelybackward, the scale is small, the two reasons that the central region research anddevelopment activities have no effect.Based on the characteristics of the medical manufacturing industry, this paperchose R&D investment, human capital, market structure, the ownership structure,foreign direct investment (FDI), government support and potential industry in sevenaspects of the mechanism of action of R&D efficiency are analyzed. Theoreticalanalysis, the conclusions are as follows: the R&D investment, human capital, marketconcentration, foreign direct investment (FDI), industrial potential in medicine R&Defficiency improving manufacturing has a strong positive effects.In front of the research on the basis, to advance our country medicinemanufacturing development, from r&d strength, human resources, the scale effect ofthe ownership structure and industrial structure, and put forward the correspondingpolicies and Suggestions.